HU-308

HU-308
Legal status
Legal status
Identifiers
CAS Number 1220887-84-2 N
PubChem (CID) 5311172
UNII 8I5L034D55 N
Chemical and physical data
Formula C27H43O3
Molar mass 415.63 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

HU-308 is a drug that acts as a cannabinoid agonist. It is highly selective for the CB2 receptor subtype, with a selectivity of over 5000x for CB2 vs CB1.[1] The synthesis and characterization took place in the laboratory of Prof. Mechoulam at the Hebrew University of Jerusalem in the late 1990s. It has analgesic effects,[2] promotes proliferation of neural stem cells,[3] and protects both liver and blood vessel tissues against oxidative stress via inhibition of TNF-α.[4][5]

United States

HU-308 is not scheduled at the federal level in the United States.[6]

Florida

"HU-308 ([(1R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol)" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[7]

See also

References

  1. Hanus, L.; et al. (1999). "HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor". Proceedings of the National Academy of Sciences of the United States of America. 96 (25): 14228–14233. Bibcode:1999PNAS...9614228H. doi:10.1073/pnas.96.25.14228. PMC 24419Freely accessible. PMID 10588688.
  2. Labuda, C.; Koblish, M.; Little, P. (2005). "Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain". European Journal of Pharmacology. 527 (1–3): 172–174. doi:10.1016/j.ejphar.2005.10.020. PMID 16316653.
  3. Palazuelos, J.; et al. (2006). "Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation". The FASEB Journal. 20 (13): 2405–2407. doi:10.1096/fj.06-6164fje. PMID 17015409.
  4. Rajesh, M.; Pan, H.; Mukhopadhyay, P.; Batkai, S.; Osei-Hyiaman, D.; Hasko, G.; Liaudet, L.; Gao, B.; Pacher, P. (2007). "Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis". Journal of leukocyte biology. 82 (6): 1382–1389. doi:10.1189/jlb.0307180. PMC 2225476Freely accessible. PMID 17652447.
  5. Rajesh, M.; et al. (2007). "CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion". American Journal of Physiology. Heart and Circulatory Physiology. 293 (4): H2210–H2218. doi:10.1152/ajpheart.00688.2007. PMC 2229632Freely accessible. PMID 17660390.
  6. 21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I.
  7. Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL


This article is issued from Wikipedia - version of the 11/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.